moxifloxacin has been researched along with desipramine in 11 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (desipramine) | Trials (desipramine) | Recent Studies (post-2010) (desipramine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 5,775 | 487 | 414 |
| Protein | Taxonomy | moxifloxacin (IC50) | desipramine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 9.18 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.35 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0031 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.35 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.1961 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 3.8 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 9.9 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4035 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 1.52 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.35 | |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | 10 | |
| Transporter | Rattus norvegicus (Norway rat) | 7.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and desipramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for moxifloxacin and desipramine
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |